Gaba 300-Ezs

Quick links

Choose a section

Quick links to important sections

Advertisements

Gaba 300-Ezs

Selected form

Advertisements
Advertisements

Overview of Gaba 300-Ezs

Quick Facts

Property Description
Active ingredient Gabapentin
Form Oral Hard Capsule
Pharmacological Class Anticonvulsant, Anti-epileptic Agent
General Purpose Stabilizing excessive neuronal activity
Origin Synthetic, GABA structural analogue

What is the Composition and Class of Gaba 300-Ezs?

Gaba 300-Ezs is a prescription-only medication classified pharmacologically as an anticonvulsant and an anti-epileptic agent, containing the single active ingredient, Gabapentin. The drug is supplied as an oral hard capsule, specifically identified by its trade name format as a 300 mg strength formulation. Gabapentin is a synthetic compound, chemically defined as 1 -(aminomethyl)cyclohexaneacetic acid, demonstrating its nature as a laboratory-developed pharmaceutical. This classification is clinically recognized for its established role in managing conditions marked by heightened nerve activity.

Is Gabapentin a Natural Compound or a Structural Analogue?

Gabapentin is not a naturally occurring substance but a synthetic structural analogue of gamma-aminobutyric acid (GABA), which functions as a major inhibitory neurotransmitter in the central nervous system. This structural resemblance is conceptual, as Gabapentin does not directly bind to or activate the major GABA receptors like some classic CNS depressants. Its classification is rooted in its unique interaction within nerve cells, specifically its affinity for the alpha 2 delta -1 subunit of voltage-gated calcium channels (VGCC). By targeting this specific subunit, the medicine stabilizes nerve signaling pathways, a property widely recognized in clinical pharmacology.

What is the General Therapeutic Purpose of Gaba 300-Ezs?

The general therapeutic purpose of Gaba 300-Ezs is the stabilization of excessive neuronal excitability within the nervous system. This is achieved through the active ingredient's ability to modulate the release of excitatory neurotransmitters. As an anticonvulsant, its typical, neutral use scenario involves the management of persistent nerve overactivity. By mitigating the speed and intensity of nerve signaling, the medicine generally helps to control abnormal electrical activity that can spread throughout the central and peripheral nerves, establishing its fundamental role as an agent for general nerve activity modulation and control.

Advertisements

What side effects are possible with Gaba 300-Ezs?

Possible Side Effects and Safety Information

The safety profile of Gaba 300-Ezs, containing Gabapentin, is defined by classifications found in official regulatory documents. Adverse reactions are grouped by frequency and the physiological system affected, establishing the expected safety characteristics of the medication.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on their observed occurrence rates in clinical studies:

Classification Examples of Documented Effects
Very Common (May affect more than 1 in 10 people) Somnolence (drowsiness), Dizziness, Ataxia (unsteadiness), Fatigue, Peripheral edema
Common (May affect up to 1 in 10 people) Viral infection, Weight gain, Tremor, Headache, Nausea, Vomiting, Constipation, Diarrhea, Diplopia (double vision)

These effects are categorized under System-Organ Classes, with Nervous System Disorders and General Disorders being the most frequently represented categories in the official label.

Documented Serious Adverse Reactions and Safety Constraints

Official prescribing information highlights specific serious adverse reactions. These include the documented risk of Suicidal Ideation and Behavior associated with anti-epileptic drugs, as well as severe systemic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). The label also contains warnings regarding Respiratory Depression, particularly when the drug is co-administered with opioids or other central nervous system (CNS) depressants.

The regulatory profile also addresses population-specific safety considerations. For instance, dosing requires adjustment in patients with renal impairment due to the drug's primary elimination route. In pediatric patients (ages 3–12), official documents note an increased occurrence of behavioral changes, including hostility and emotional lability.

Furthermore, the profile explicitly notes the potential for abuse and the development of physical dependence and indicates that common effects like somnolence and dizziness may be more prominent early in treatment or during dose titration.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented manifestations of overdose and the required emergency actions, strictly based on government regulatory sources.

Element Official Regulatory Documentation Statement
Documented presentations Somnolence (drowsiness), Slurred speech, Ataxia (impaired coordination), Diplopia (double vision), Lethargy, and Diarrhea.
Physiological systems affected Central Nervous System (CNS) and the Respiratory System (respiratory depression).
Risk factors Increased risk with co-ingestion of CNS depressants (e.g., opioids), Impaired Renal Function, or in Elderly Individuals.
Immediate help required Seek immediate medical attention for breathing difficulties (slow, shallow breathing, unresponsiveness) or suspected overdose.
Classification Aspect Official Regulatory Documentation Statement
Severity classification Overdose can range from mild toxicity to severe presentations, including Coma and Death.
Antidote status No specific antidote is known.

Official Overdose Statements

The regulatory profile details that the primary risk beyond acute CNS manifestations is severe respiratory depression, a serious and potentially fatal outcome. Emergency services or Poison Control must be contacted immediately if symptoms of extreme sedation or difficulty breathing are observed. Management focuses on providing symptomatic and supportive care. Procedures such as gastric lavage or the use of hemodialysis may be indicated to remove the drug, particularly for severe cases or for individuals with compromised renal function.

This structured information provides the necessary, label-based facts regarding overdose presentation and mandatory help-seeking conditions.

Advertisements

Therapeutic Uses of Gaba 300-Ezs

What Gaba 300-Ezs Treats: Main Uses and Benefits

The primary role of Gaba 300-Ezs is commonly used across therapeutic domains where symptoms of increased neurological activity interfere with functional stability. The medication is commonly used to help with symptomatic manifestations in conditions involving heightened physiological stress.

Used for Managing Recurrent Partial Seizures

Gaba 300-Ezs is considered relevant for easing symptom clusters associated with acute or episodic changes in the central nervous system, particularly for partial-onset seizures in adults and pediatric patients (aged 3 and older). The medication supports stabilization of symptoms related to heightened physiological activity, and may assist with managing the recurrence of these disruptive episodes, which supports general well-being.

“The primary therapeutic focus is on symptom management in conditions involving symptoms of increased neurological or muscular activity.”

Applied for Symptom Management of Chronic Peripheral Nerve Pain

The medicine is applied in addressing chronic, persistent pain—such as Postherpetic Neuralgia (PHN)—that results from nerve damage, which are symptoms related to physical discomfort. It is relevant for easing challenging manifestations like burning and stabbing pain. This symptomatic relief generally helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability.

Gaba 300-Ezs is primarily relevant for managing three key symptomatic domains: conditions involving recurrent or episodic manifestations, conditions presenting with systemic or localized discomfort (such as Postherpetic Neuralgia), and conditions associated with acute or disruptive episodes (such as RLS).

Quick Fact: Supportive Management for Neuropathic Pain
Symptom Type: symptoms related to physical discomfort
Use Context: relevant when supportive symptom management is appropriate
Benefit Focus: Provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gaba 300-Ezs — Official Regulatory Information

Populations for whom use is contraindicated:

Use is contraindicated in patients with a known hypersensitivity to the active ingredient Gabapentin or any of the product's components. Patients who previously experienced a severe cutaneous adverse reaction (SCAR), such as DRESS, must not use this medicine again.


Eligibility Scope

Classification Population Group Regulatory Status
Adults Postherpetic Neuralgia and Partial-Onset Seizures Established Use
Pediatric Patients Partial-Onset Seizures Established Use (Ages 3 years and older)
Children Partial-Onset Seizures Use not established (Ages under 3 years)
Renal Function Compromised Creatinine Clearance Requires conditional use (Dose adjustment mandated)
Older Adults General Use (over 65 years) Requires special consideration (Adjustment for renal decline)
Pregnancy/Lactation Women of Childbearing Potential Not recommended (Use only if benefits outweigh risks)

Resulting Eligibility Structure

Official regulatory documents define a clear use profile for Gaba 300-Ezs. The medicine is contraindicated by known patient hypersensitivity. Use is established for adults and for children aged three years and older for partial-onset seizures. For patients with impaired renal function, the official label dictates a conditional use status, mandating that the dose be adjusted in proportion to their creatinine clearance. Additionally, use in women who are pregnant or breastfeeding is not recommended unless the treating clinician determines the potential benefit outweighs the documented risks.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medication's interaction profile is defined by both pharmacodynamic and pharmacokinetic effects with other substances. The primary concern is the increased risk of central nervous system (CNS) depression when co-administered with other depressants.

Documented Pharmacodynamic Interactions

Concomitant use with other CNS depressants increases the risk of severe sedation and respiratory depression. This includes medicines such as opioids, benzodiazepines, certain antihistamines, and sedating antipsychotics. This risk is considered more serious for elderly patients or those with pre-existing respiratory risk factors. Official labeling requires alcohol to be strictly avoided, as it can accelerate drug release and increase the likelihood of severe side effects such as sleepiness and nausea.

Documented Pharmacokinetic Interactions

Antacids containing aluminum hydroxide or magnesium hydroxide can significantly reduce the amount of the active drug absorbed into the body. To prevent this reduction in effectiveness, the official regulatory recommendation is that antacids should be taken at least 2 hours after this product. Because this medication has a unique extended-release formulation, regulatory documents state it is not interchangeable with other gabapentin products.

Advertisements

Mechanism of Action

How Gaba 300-Ezs Works

The action of Gaba 300-Ezs (Gabapentin) is purely mechanistic, focusing on reducing the intensity of communication between nerve cells through a highly specific molecular target.

Presynaptic Voltage-Gated Calcium Channel Modulation

The primary mechanism involves the high-affinity binding of the molecule to the alpha-2-delta-1 (alpha2delta-1) subunit of presynaptic Voltage-Gated Calcium Channels ( VGCCs). This interaction modulates the function of these channels, leading to a restricted influx of calcium ions ( Ca^2+) necessary for signal transmission within the nerve cell terminal. This molecular change results in lower levels of subsequent nerve activity.

Attenuating Excitatory Neurotransmitter Release

By reducing the critical Ca^2+ required for synaptic vesicle fusion and exocytosis, the drug decreases the release of excitatory chemical messengers like Glutamate and Norepinephrine into the synaptic cleft. This downstream effect on neurotransmitter release results in decreased propagation of rapid, synchronized nerve firing. This entire cascade achieves the core physiological consequence: the attenuation of high-frequency neuronal activity within the central nervous system.

Advertisements

Dosage and Administration Information

Gaba 300-Ezs capsules contain the active ingredient gabapentin and should be used exactly as prescribed by your healthcare provider. This medication is typically prescribed for postherpetic neuralgia (nerve pain following shingles) and as an add-on therapy for partial-onset seizures in adults and children over 3 years old.

General Administration Instructions

  • Swallow Whole: Capsules must be swallowed whole with water. Do not cut, crush, or chew them.
  • With or Without Food: You may take Gaba 300-Ezs with or without food. However, taking it the same way each time can help maintain consistent drug levels.
  • Dosing Schedule: Take your doses at evenly spaced intervals throughout the day. If you are taking the medicine three times daily for seizures, the maximum time between any two doses should not exceed 12 hours to help prevent the risk of increased seizure activity.

Initiation and Discontinuation

  • Starting Dose: Treatment typically begins with a low initial dose that is gradually increased (titrated) over several days to allow your body to adjust to the medication and minimize potential side effects. This initial titration schedule will be determined by your prescriber.
  • Discontinuation: If the medication needs to be stopped, it must be done gradually over a minimum of one week, or a longer period as determined by your healthcare provider. Do not stop taking this medication abruptly, as this may increase the risk of withdrawal seizures.
Important Considerations Guidance
Missed Dose Take the missed dose as soon as you remember. If it is close to the time for your next scheduled dose (within 2 hours), skip the missed dose and resume your regular schedule. Do not take a double dose to make up for a missed one.
Antacids If you take aluminum or magnesium-based antacids, wait at least 2 hours after taking the antacid before you take your gabapentin dose. This separation is necessary because antacids can decrease the absorption of gabapentin.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Single-Agent Use

This section outlines the key findings from trials that evaluated Gaba 300-Ezs (the compound) as a standalone treatment in chronic conditions.

Efficacy and Pain Management

Multiple randomized controlled trials (RCTs) evaluated the compound's effects, particularly in neuropathic conditions, rather than general inflammatory conditions. Research explored whether the compound was associated with reductions in reported pain scores across several metrics, including the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).

For some chronic pain conditions, RCTs of 12 weeks' duration provided evaluations of pain and mobility outcomes. A common objective in these studies was to assess whether the compound's administration was associated with changes in inflammation biomarkers. This body of research was conducted to evaluate the compound in chronic pain models, though some specific chronic pain trials found no significant difference in pain reduction compared to placebo.

Tolerability and Safety Findings

The tolerability and safety characteristics of the compound have been evaluated across various long-term and short-term studies. The main objective of these studies was to evaluate changes in patient function and monitor adverse events over defined observation periods. Study results noted that the most frequently noted events reported in the study were transient dizziness, somnolence, and gastrointestinal discomfort.

Research on Combination Therapy

Studies have also evaluated the compound's effects when administered alongside established therapeutic approaches, such as opioid analgesics or physiotherapy.

Compound with Physiotherapy

Studies assessed the effects of the drug when used in combination with physiotherapy, particularly in localized pain syndromes like carpal tunnel syndrome. These evaluations focused on measures of physical function and quality of life (QoL) metrics.

In some postoperative settings, combination regimens involving the compound were associated with a statistically significant decrease in time required to complete physical therapy goals and with reduced reliance on oral opioid consumption.

Tolerability of Combined Use

The tolerability of the combination was assessed as a core focus of phase III trials. While evaluations noted specific safety considerations related to high doses in certain patient subgroups, the research reviewed documented few reported risk findings. Studies included a comparison group (e.g., standard NSAID treatments or placebo) to evaluate any differences in reported adverse events, with some trials noting a reduction in common opioid-related side effects such as nausea/vomiting and pruritus when used in combination.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gaba 300-Ezs (FAQ)


Q: How quickly does Gaba 300-Ezs start to work after taking it?

According to official product information, the active ingredient in Gaba 300-Ezs may be relatively fast-acting in terms of its presence in the body. However, achieving the full therapeutic benefit for chronic conditions, such as nerve pain or seizures, often takes longer. Treatment typically involves a gradual dose adjustment over several days or weeks, which is intended to help the body adjust.

Q: Can Gaba 300-Ezs cause weight gain?

Yes. Weight gain is listed as a common side effect observed during clinical studies with Gaba 300-Ezs. Regulatory data indicates that this documented effect can be related to both the dose and the duration of treatment.

Q: How long is Gaba 300-Ezs usually taken for?

Gaba 300-Ezs is used for chronic conditions, and official clinical trials have assessed its use over periods lasting up to several years. The required duration of treatment is not standardized but is determined by the specific condition being managed and the individual clinical assessment by a prescriber.

Q: Can older adults (seniors) safely use Gaba 300-Ezs?

Yes, older adults can use this medicine, but regulatory documents mandate special consideration. Since Gaba 300-Ezs is eliminated through the kidneys, the dose must typically be adjusted for older adults based on their kidney function. This adjustment helps manage drug levels, which is a required consideration in this population.

Q: Is it common to feel tired or dizzy when starting Gaba 300-Ezs?

Yes, it is common. Official labeling classifies somnolence (drowsiness) and dizziness as 'very common' side effects. This classification indicates they are among the most frequently reported side effects, and they are often most prominent when treatment begins or when the dose is being increased.

Q: Does Gaba 300-Ezs have a risk of dependence or withdrawal?

Official regulatory information includes warnings about the potential for abuse and the development of physical dependence with Gaba 300-Ezs. For this reason, official guidance recommends that the medication should not be stopped suddenly, as abrupt discontinuation can lead to withdrawal symptoms, including an increased risk of seizures.

Q: Can I take Gaba 300-Ezs while pregnant or breastfeeding?

Regulatory information states that use during pregnancy is generally not recommended because documented risks to the fetus exist. The medicine is also known to pass into human milk. A careful clinical evaluation is required to determine whether the potential benefits of continuing the medication outweigh these known potential risks.

Q: What happens if I miss a dose of Gaba 300-Ezs?

For patients using Gaba 300-Ezs to manage seizures, official directions state that the interval between any two doses should not exceed 12 hours. If doses are missed or delayed beyond this time frame, it may increase the risk of fluctuations in nerve activity.

Q: Does Gaba 300-Ezs require any special monitoring or blood tests?

Yes, monitoring is required for specific patient groups. Since Gaba 300-Ezs is eliminated by the kidneys, official prescribing documents mandate the monitoring of kidney function (creatinine clearance). This allows the healthcare provider to determine and maintain the appropriate, condition-specific dose.

Q: How does Gaba 300-Ezs work in the brain?

Gaba 300-Ezs works in the central nervous system by binding to a specific site on nerve cells. This action reduces the amount of excitatory chemical messengers (neurotransmitters) that are released, which helps to stabilize and calm excessive or fast-paced nerve activity in the brain and nervous system.

Q: Is Gaba 300-Ezs a controlled substance?

Federally, in the United States, Gaba 300-Ezs is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). However, due to its noted potential for abuse and dependence, several individual U.S. states have independently classified the active ingredient as a Schedule V controlled substance.

Q: Is Gaba 300-Ezs the same thing as the supplement GABA?

No, they are not the same. The active ingredient in Gaba 300-Ezs is a synthetic structural analogue of the neurotransmitter GABA. While structurally similar, the medicine does not directly bind to or activate the major GABA receptors, distinguishing its mechanism of action from the naturally occurring compound.

Q: Will Gaba 300-Ezs affect my ability to drive or operate machinery?

Official warnings state that Gaba 300-Ezs may significantly affect the central nervous system due to side effects like dizziness and somnolence (drowsiness). Official product information advises caution regarding driving or operating complex machinery until patients know how the medication affects them.

Q: Are there any specific foods or drinks I should avoid while taking Gaba 300-Ezs?

Official regulatory labeling states that alcohol should be strictly avoided during treatment due to a heightened risk of severe central nervous system side effects like severe drowsiness. Additionally, taking aluminum or magnesium-based antacids must be separated from your dose by at least two hours, as they can reduce the amount of medicine absorbed.

Q: What is the difference between Gaba 300-Ezs and other medicines for nerve pain?

Gaba 300-Ezs is chemically classified as an anticonvulsant and works by modulating calcium channels in nerve cells to stabilize overactive nerve signaling. This mechanism of action is distinct from that of traditional anti-inflammatory painkillers, which typically work by blocking chemical pain signals or reducing inflammation.

Q: Is Gaba 300-Ezs safe for people who have kidney issues?

Official regulatory documents confirm that Gaba 300-Ezs is safe for use in patients with kidney issues, provided that the dose is carefully adjusted. Because the medicine is eliminated entirely by the kidneys, the dose must be customized by the prescriber to match the patient's level of kidney function.

Q: How long does Gaba 300-Ezs stay in your system after stopping it?

Pharmacokinetic data shows that the elimination half-life of Gaba 300-Ezs is typically between five to seven hours in individuals with normal kidney function. This time is extended in patients with any degree of impaired kidney function.

Q: Are there any known long-term effects of taking Gaba 300-Ezs?

Long-term studies have been conducted to assess the drug’s safety profile over extended periods. Official reports indicate that the most frequently noted long-term effects are generally consistent with the known common side effects, such as weight gain, drowsiness, and unsteadiness, which are monitored over the course of treatment.

Q: Does Gaba 300-Ezs affect sleep or cause insomnia?

The most commonly reported effect on the central nervous system is somnolence, or drowsiness, which is a very common side effect. Insomnia, while reported in some clinical studies, is not listed among the very common or common side effects in the core regulatory classifications.

Q: Is Gaba 300-Ezs used to treat restless legs syndrome?

The active ingredient in Gaba 300-Ezs, gabapentin, is officially indicated only for the treatment of partial-onset seizures and nerve pain following shingles. While a modified version of the molecule is approved for Restless Legs Syndrome (RLS), Gaba 300-Ezs itself does not carry that official indication.

Q: Why is the number '300' in the drug name?

The number '300' in the name Gaba 300-Ezs signifies the exact strength of the medication in milligrams (mg). This specific capsule formulation contains 300 milligrams of the single active ingredient, gabapentin.

Q: Can Gaba 300-Ezs affect my mood or cause depression?

Regulatory documents carry a serious warning regarding the potential for Suicidal Ideation and Behavior associated with anti-epileptic drugs. Additionally, behavioral changes, such as emotional lability and hostility, have been reported in children aged 3 to 12 taking this medication.

Q: Does Gaba 300-Ezs cause dry mouth?

Dry mouth is not listed as a very common or common adverse reaction in the core regulatory classifications of Gaba 300-Ezs. While it may be reported as a less frequent event, it is not one of the typical side effects documented in clinical trials.

Q: How often do people stop taking Gaba 300-Ezs due to side effects?

Regulatory documents from clinical trials report the percentage of patients who discontinued treatment due to experiencing adverse events, such as dizziness and somnolence. This attrition rate is documented to vary depending on the specific condition being treated and the dose of the medicine.

Q: Can people with a history of substance abuse use Gaba 300-Ezs?

Official warnings note the drug's potential for abuse and the development of physical dependence. This is an important factor that a healthcare provider is required to consider during patient evaluation, particularly for individuals with a known history of substance abuse.

Q: Is Gaba 300-Ezs metabolized by the liver?

No. Official pharmacokinetic information states that the active ingredient in Gaba 300-Ezs is not significantly metabolized in humans. The medicine is primarily excreted unchanged through the urine.

Q: Are there any supplements that interact negatively with Gaba 300-Ezs?

Regulatory warnings specifically address interactions with antacids and prescription central nervous system depressants. Patient information leaflets often advise reviewing the use of herbal remedies or supplements that cause drowsiness, as this can worsen the side effects of Gaba 300-Ezs.

Q: Is Gaba 300-Ezs used for conditions other than nerve pain and seizures?

The medicine is officially indicated only for the treatment of postherpetic neuralgia (nerve pain) and as add-on therapy for partial-onset seizures. Official labeling does not list other conditions for which Gaba 300-Ezs is approved.

Q: Does Gaba 300-Ezs lose its effectiveness over time?

General regulatory documents do not address patient-specific changes in effectiveness over time (clinical tolerance or tachyphylaxis). The official information confirms the drug is intended for chronic use.

Q: Can Gaba 300-Ezs affect birth control pills?

According to official regulatory information regarding drug interactions, the active ingredient in Gaba 300-Ezs does not affect the effectiveness of oral contraceptives (birth control pills). However, severe gastrointestinal side effects like vomiting or diarrhea may reduce the effectiveness of the birth control pill.

Q: What regulatory bodies have approved Gaba 300-Ezs for use?

The active ingredient in Gaba 300-Ezs has been approved by major governmental regulatory bodies for its indicated uses. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which assess efficacy and safety before approving a medicine for public use.

Q: Is Gaba 300-Ezs an opioid?

No. Gaba 300-Ezs is classified pharmacologically as an Anticonvulsant/Anti-epileptic agent. It is a structural analogue of GABA and does not work by binding to or affecting opioid receptors.

Advertisements

How should Gaba 300-Ezs be stored and disposed of?

How to Store and Dispose of Gaba 300-Ezs

The storage of Gaba 300-Ezs (gabapentin capsules) must strictly adhere to the conditions documented in official regulatory labeling to ensure product stability and integrity.


Storage and Protection

The medication must be maintained at Controlled Room Temperature, specifically between 20 and 25 C (68 to 77 F), with brief excursions permitted up to 30 C. To protect the capsules, the product must be stored in a tight and child-resistant container.

It is a mandatory requirement that Gaba 300-Ezs and all medicines be kept out of the reach of children.


Disposal Requirements

Disposal of any unused or expired product must follow the manufacturer’s patient labeling instructions or guidance from a pharmacist. Unused medicine should generally not be flushed down a sink or toilet, in accordance with established environmental protection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gaba 300-Ezs found in:

A-Z Index: